Genmab (GE91) AI Stock Analysis

Top Page

Genmab

(Frankfurt:GE91)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Commercial growth and operating leverageStrong commercial momentum across EPKINLY, DARZALEX and the broader portfolio is supporting a meaningfully higher revenue outlook. The limited increase in planned operating expenses relative to sales growth also indicates potential operating leverage, strengthening the durability of future profit expansion.

Negative Factors

Material margin compressionThe sharp decline in operating and net margins shows that recent revenue growth is not translating proportionally into earnings. If lower profitability persists while Genmab continues investing in launches and research, internal funding capacity and the pace of earnings compounding could remain constrained.

Genmab (GE91) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 35.09B
Dividend Yield: ―
Average Volume (3M): 124
Price to Earnings (P/E): 45.6
Beta (1Y): 0.70
Revenue Growth: 14.22%
EPS Growth: -40.65%
Country: Germany
Employees: 3,119
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Genmab Business Overview & Revenue Model

Company Description

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The com...

Genmab Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:100.00%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentPositive

Genmab presented a strongly positive commercial and financial performance in H1 2026 — double-digit revenue and operating profit growth, upgraded full-year guidance, robust Epkinly momentum, meaningful product sales (DARZALEX, EPKINLY, TIVDAK), and multiple late-stage clinical advances including a positive Phase III PFS readout and new Phase III initiations. The company also acknowledged execution uncertainties: several data readouts remain event-driven or immature (OS not yet mature), competition across key indications is intensifying, some trial timing/readout clarifications raised investor questions, and integration/IP/tax factors introduce near-term modeling uncertainty. On balance the operational and financial momentum and near-term catalyst calendar outweigh the challenges, supporting a constructive outlook.

Positive Updates

Strong Revenue Growth

Total revenue grew 25% year-over-year in H1 2026, with updated full-year 2026 revenue guidance raised to $4.3–$4.5 billion (midpoint ~19% YoY growth). Management increased the midpoint by ~$195 million versus prior guidance (~equally split between DARZALEX and EPKINLY).

Negative Updates

Timing Uncertainty and Readout Delays

Some readouts were pushed or clarified later than previously guided: petosemtamab second/third-line readout now expected in Q1 2027 (management cited event-driven overall survival endpoint and upsizing), and investors questioned a perceived ~1-year delay to the EPCORE DLBCL-2 interim analysis versus external expectations.

Company Guidance

Genmab updated 2026 guidance after a strong H1: total revenue grew 25% YoY and adjusted operating profit rose 18% in H1, proprietary portfolio sales were $396m (+37% YoY), EPKINLY sales were $312m (+48% YoY, +28% QoQ), TIVDAK was $84m, DARZALEX grew 21% and the remainder of the portfolio grew 35% YoY; management now expects full‑year 2026 revenue of 4.3–4.5 billion (≈19% YoY at the midpoint) — a ~$195m midpoint upgrade split roughly equally between DARZALEX and EPKINLY — operating profit of $1.1–1.4 billion, operating expense guidance with a midpoint of $2.88 billion (OpEx guidance up only ~2% vs prior), and overall guidance that is ~5% higher revenue and ~7% higher operating profit versus the previous outlook; H1 effective tax rate was 3.6% (tax expense $13m) and is expected to normalize over 12–18 months.

Genmab Risk Analysis

Genmab disclosed 51 risk factors in its most recent earnings report. Genmab reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

2 New Risks

1.The substantial majority of our revenue comes from royalties on sales of DARZALEX, and our patents underlying these royalties will start to expire in the late 2020s.Q4, 2024

2.We are subject to risks as a result of our multinational operations.Q4, 2024

Genmab Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:GE91 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	78Outperform	$9.36B	20.09	72.30%	―	76.08%	634.54%
ZYME	59Neutral	$2.03B	-14.16	-72.07%	―	-69.78%	-106.07%
BNTX	53Neutral	$22.15B	-11.50	-9.16%	―	-1.05%	-395.95%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LEGN	50Neutral	$4.19B	-43.26	-8.70%	―	59.59%	71.96%
XNCR	47Neutral	$2.22B	-13.74	-28.66%	―	-28.56%	10.25%

* Healthcare Sector Average

Performance Comparison

DE:GE91 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:GE91	Genmab (Otc)	50.00	25.40	103.25%
XNCR	Xencor Inc.	29.82	15.88	113.92%
TGTX	TG Therapeutics	61.18	27.49	81.60%
ZYME	Zymeworks	28.61	9.72	51.46%
BNTX	Biontech Se Sponsored Adr	88.17	-15.78	-15.18%
LEGN	Legend Biotech Corporation	21.63	-10.50	-32.68%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Genmab AI Stock Analysis